PIPELINE A broad pipeline of unique, world-class candidates with the potential to revolutionize the prevention and treatment of cancer and infectious disease. Our AI-technology enables a high level of scalability, offering the potential to expand our portfolio and our proprietary platforms to the benefit of patients worldwide.

Pipeline for 2022 to 2025

EVX-01 is a peptide-based neoantigen cancer therapy intended for the first-line treatment of a variety of metastatic and unresectable melanoma. Whilst checkpoint inhibitors have revolutionized the treatment of melanoma, too many patients still die from this cancer. EVX-01 has shown promising clinical results in, with patients benefitting - and even recovering - after receiving the therapy. Evaxion is now conducting a large phase 2 clinical trial with this candidate.

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.